dapsone / Generic mfg. - LARVOL DELTA

A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes. (PubMed, Clin Toxicol (Phila)) - "Among 169 patients (median age 43 years; 59.17% male), the leading causes were dapsone (30.18%) and propanil (27.22%), followed by herbal and food-related agents...Shock at presentation may prognosticate a fatal outcome. Early diagnosis, timely therapy, and aggressive management of systemic complications are required to improve the patients' clinical outcomes."

Journal • Retrospective data • Cardiovascular • Critical care • Hematological Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock

Double Trouble… or Double Triumph? Dual Biologic Therapy in Refractory Hidradenitis Suppurativa (AAD 2026) - "Adalimumab, secukinumab, and bimekizumab are currently FDA-approved for moderate-to-severe HS, with adalimumab demonstrating response rates of 42–59%...He had minimal response to doxycycline, benzoyl peroxide wash, and clindamycin, and subsequently failed adalimumab, secukinumab, acitretin, dapsone, cefadroxil, prednisone, laser hair removal, and topical agents over two years. Given inadequate disease control, infliximab was added to ongoing secukinumab... Dual biologic therapy may represent a promising option for patients with severe, refractory HS unresponsive to monotherapy with currently available systemic treatments, including FDA-approved biologics used individually. Larger studies are needed to clarify long-term efficacy and safety."

Acne Vulgaris • Aesthetic Medicine • Conjunctivitis • Dermatology • Dry Eye Disease • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Refractory nasal pemphigus vegetans treated with dupilumab in a patient with multiple contraindications to first-line therapies (AAD 2026) - "Management was complicated by steroid-induced hyperglycemia, dapsone-associated methemoglobinemia, thiopurine methyltransferase deficiency, and a rituximab biosimilar infusion reaction...Based on emerging data on dupilumab’s use towards remission induction in refractory pemphigus vulgaris, we initiated dupilumab 300mg every 4 weeks combined with low-dose mycophenolate mofetil...Treatment was discontinued due to persistent gastrointestinal discomfort, and nasal lesions recurred 13 weeks later despite the use of topical tacrolimus 0.01% ointment and clobetasol 0.05% ointment twice daily. Although prior data on dupilumab for pemphigus vegetans is lacking, dupilumab may represent a steroid-sparing option for pemphigus vegetans in patients who cannot tolerate rituximab or its biosimilars. Prospective research should evaluate dupilumab’s efficacy in achieving and maintaining pemphigus vegetans remission."

Clinical • Bullous Pemphigoid • Chronic Rhinosinusitis With Nasal Polyps • Dermatopathology • Diabetes • Gastrointestinal Disorder • Hematological Disorders • Immunology • Metabolic Disorders • Nasal Polyps • Otorhinolaryngology • Pemphigus Vulgaris • Respiratory Diseases • Sinusitis • Type 2 Diabetes Mellitus

Eosinophilic Annular Erythema with Marked Hypereosinophilia in an Adult: A Case Report of Successful Dupilumab Therapy (AAD 2026) - "While therapies such as antimalarials and dapsone have shown variable success, dupilumab has recently demonstrated promise in a small number of case reports for achieving sustained remission...Treatment was initiated with topical triamcinolone, oral antihistamines, and off-label dupilumab...It highlights the need to distinguish EAE from Wells syndrome or hypereosinophilic syndrome in such presentations. Furthermore, the patient’s response to dupilumab supports the growing body of literature indicating that IL-4/IL-13 inhibition may be an effective therapeutic strategy in refractory eosinophilic annular erythema."

Case report • Clinical • Dermatology • Eosinophilia • Hematological Malignancies • Hypereosinophilic Syndrome • Immunology • Infectious Disease • Nephrology • Pruritus • Renal Disease • Vasculitis • IL13 • IL4

Ulcerative Necrobiosis Lipoidica in the Setting of Oropharyngeal Epstein-Barr Virus Positive Diffuse LargCell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report (AAD 2026) - "Anti-inflammatory topical clobetasol 0.05% ointment was initiated as well as a saline based solution containing hypochlorous acid for wound cleansing. Due to secondary infection, the patient’s topical regimen was modified to include gentamicin 0.1% ointment and mupirocin 2% ointment followed by eventual broad-spectrum IV antibiotics. Notably, dapsone was avoided due to known G6PD as well as other immunosuppressants in the setting of DLBCL and ongoing chemotherapy with rituximab, cyclophosphamide, doxorubicin, (vincristine), and prednisone (R-CHOP) which had induced neutropenia and thrombocytopenia...Additionally, pegfilgrastim and platelet infusions for neutropenia and thrombocytopenia were administered after initiating R-CHOP. The noninfectious granulomatous reactions may have been an early sign of the underlying lymphoma, suggesting DLBCL as a contributing factor to NL disease pathogenesis."

Case report • Clinical • B Cell Lymphoma • Diabetes • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • Thrombocytopenia

Continuing Dapsone in the Setting of Anemia: A Multidisciplinary Approach to Dermatitis Herpetiformis (AAD 2026) - No abstract available

Anemia • Dermatitis • Dermatology • Hematological Disorders • Immunology

Dapsone Syndrome Relapse: Unraveling a Complex Case (APASL 2026) - No abstract available

Clinical

Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study. (PubMed, PLoS Negl Trop Dis) - "In our study, dapsone-free alternative regimens demonstrated comparable clinical efficacy and safety to standard MDT in MB patients, providing a viable option for HLA-B*13:01 carriers. These findings, limited by the observational design and regimen heterogeneity, warrant further investigation in prospective trials."

HEOR • Journal • Immunology • HLA-B

A Retrospective US Claims Database Study Assessing Treatment Patterns and Bleeding Episodes in Patients with Previously Treated Primary Immune Thrombocytopenia (THSNA 2026) - "Previously treated patients were defined as currently receiving ITP treatment, with 1 prior therapy of OCS, IVIg, IV anti-D, or platelet transfusion, and ≥1 prior therapy of TPO-RA, rituximab, fostamatinib, anti-CD38 monoclonal antibodies, immunosuppressants, danazol, dapsone, bortezomib, vinca alkaloid, or splenectomy after the initial diagnosis. According to this US-based claims study, many patients with primary ITP experience bleeding episodes requiring treatment with rescue therapies, despite receiving first- and second-line treatments, implying a clinically significant decrease in platelets, and highlighting the unmet need for more effective therapies for patients with primary ITP. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Claims database • Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Rare Diseases • Thrombocytopenia • Thrombocytopenic Purpura

Sneddon-Wilkinson Disease in Skin of Color: A Case Managed with Dapsone (AAD 2026) - "This case illustrates the diagnostic challenges of SWD in patients with skin of color, in whom erythema may be subtle and lesions easily mistaken for infectious or autoimmune blistering disorders. Biopsy with H&E and immunofluorescence is critical to establishing the diagnosis. While dapsone remains first-line therapy, our patient's course underscores the relapsing nature of SWD and the need for adjunctive treatment in refractory disease."

Clinical • Hidradenitis Suppurativa • Immunology • Metabolic Disorders

Dasatinib-induced small-vessel vasculitis in a patient with chronic myeloid leukemia (AAD 2026) - "Suppressive therapy such as dapsone was considered, but the patient elected reactive management with prednisone during flares. While keratosis-pilaris like eruptions and neutrophilic dermatoses have been associated with dasatinib, to our knowledge, this represents the first biopsy-confirmed cutaneous small-vessel vasculitis associated with dasatinib (1). This case underscores the importance of considering dasatinib in the differential for recurrent painful vasculitic eruptions and demonstrates the diagnostic value of biopsy in the evaluation of our oncologic patients."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Immunology • Leukemia • Neuroendocrine Tumor • Solid Tumor • Vasculitis

Granuloma Faciale: Common Histological Findings and Treatment Options (AAD 2026) - "First line treatments include topical or intralesional corticosteroids, and topical calcineurin inhibitors. Alternative therapies have been reported with various efficacy including topical and oral dapsone, topical ruxolitinib, hydroxychloroquine, etc. Cryotherapy, surgical excision, ablative or pulse dye laser have also been reportedly used, but carry the risk of scarring."

Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Vasculitis

Cocaine-Induced Granulomatous Lesion Mimicking Facial Pyoderma Gangrenosum and Granulomatosis with Polyangiitis (AAD 2026) - "The patient was managed with high-dose corticosteroids, cyclosporine and dapsone which yielded improvement. CIMDL can mimic PG and GPA both clinically and histopathologically, delaying correct diagnosis. Unlike GPA or PG, where immunosuppression is central, CIMDL is best managed by strict cocaine cessation, the only proven therapy, supported by wound care and infection control. The scarcity of effective treatments underscores the importance of awareness and prevention in this condition."

Infectious Disease • Pyoderma Gangrenosum • Rare Diseases • Vasculitis • MPO

Bullous eosinophilic annular erythema: a case report. (AAD 2026) - "The patient was initiated on hydroxychloroquine 400 mg daily, with complete resolution of the lesions. In refractory cases, dapsone and classic immunosuppressants such as cyclosporine, methotrexate, and mycophenolate mofetil have been employed. Recent reports have described successful treatment with JAK inhibitors and biologics targeting Th2-mediated inflammation, including mepolizumab, benralizumab, and dupilumab⁵⁻⁶."

Case report • Clinical • Dermatology • Immunology • Inflammation

Anti-Inflammatory Role of Radiation Therapy for treatment of Refractory Erosive Pustular Dermatosis of the Scalp (AAD 2026) - "While the management of refractory cases includes solutions of vitamin A derivatives, calcipotriol, dapsone, and tacrolimus, our results suggest that lower-dose radiation therapy may have anti-inflammatory effects on dermatological conditions. This is consistent with lower-dose radiation therapy in our lab's previous use in COVID-19. We further compare variable clinical manifestations, pathophysiology, and management of EPDS and suggest lower-dose superficial radiation therapy as an alternative for refractory EPDS on a case-by-case basis."

Alopecia • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Squamous Cell Carcinoma

Bullous Systemic Lupus Erythematosus in a Southeast Asian Cohort: High Systemic Association Driving Systemic Therapy. (PubMed, Asian Pac J Allergy Immunol) - "This study and literature review highlight that, although BSLE is an uncommon cutaneous manifestation of SLE, it is strongly associated with systemic involvement, particularly renal and hematologic disease, which often necessitates treatment with immunosuppressive agents."

Journal • Cutaneous Lupus Erythematosus • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Cutaneous Rosai-Dorfman disease: a case report of disease limited only to skin. (PubMed, Dermatol Reports) - "Various treatment options are described, including surgical excision, cryotherapy, corticosteroids, antibiotics, methotrexate, and dapsone. In our case, we used CO2 laser treatment successfully. To our knowledge, this is only the second case where CRDD lesions were treated successfully with CO2 laser."

Journal • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Lyme Disease • Lymphoma • Oncology • Rare Diseases

Unveiling Lepromatous Leprosy in a Non-endemic Region: A Case of Delayed Diagnosis and Effective ROM (Rifampin, Ofloxacin, and Minocycline) Therapy. (PubMed, Cureus) - "ROM therapy demonstrated a favorable treatment outcome, presenting a well-tolerated alternative to the World Health Organization's standard MDT regimen with rifampin, dapsone, and clofazimine. Clinicians should maintain a high index of suspicion for leprosy in patients with chronic, non-healing skin lesions, particularly when there is a history of travel to endemic regions, even many years prior. Further research comparing ROM and MDT regimens is warranted."

Journal • Dermatology • Infectious Disease

Safety and effectiveness of topical dapsone in acne treatment: A review. (PubMed, J Family Med Prim Care) - "It showed a favorable safety profile, even in patients with comorbidities, such as G6PD deficiency. We conclude that topical dapsone is safe, effective, and well tolerated in the treatment of acne, contrary to its oral form."

Journal • Review • Acne Vulgaris • Dermatology • Metabolic Disorders • Rosacea

Management of Treatment Resistant EGFR Inhibitor-Induced Papulopustular Exanthema With Isotretinoin and Dapsone. (PubMed, Australas J Dermatol) - "Both isotretinoin and dapsone are effective, well-tolerated options for managing tetracycline-resistant EGFRi-induced papulopustular eruptions. Isotretinoin showed a trend toward faster improvement, while ultimate response rates were similar. Maintaining EGFRi therapy, even at reduced doses, in conjunction with dermatology treatment was associated with superior dermatological outcomes and higher survival at follow-up compared with cessation of EGFRi treatment, highlighting the importance of proactive dermatologic intervention to support oncologic treatment continuity."

Journal • Dermatology • Hematological Disorders • Oncology

Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety. (PubMed, Br J Haematol) - "Age, sex, previous treatment numbers and response, ITP types, baseline platelets and concurrent treatments were not associated with a response. Two patients needed dapsone discontinuation due to adverse events."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Pediatrics • Thrombocytopenia • Thrombocytopenic Purpura

Sustainable antibacterial nanocoating from polycaprolactone grafted with dapsone and silver nanoparticles for boosting the properties of bagasse paperboard for active food packaging. (PubMed, RSC Adv) - "Moreover, the treated BPs demonstrated superior antibacterial activity, which effectively killed microbes and inhibited their growth within an inhibitory zone ranging from 14 to 33 mm, depending on the microbe and sample type. In summary, PCL grafting is influential, and applying PCL-DAP-based Ag NPs as a nanocoating to hydrophilic BPs presents a highly promising strategy for antimicrobial food packaging applications."

Journal

Type 2 Lepra Reaction Following Antituberculosis Treatment Initiation in an Elderly Male With Coexisting Hansen's Disease: A Case Report. (PubMed, Respirol Case Rep) - "Intravenous hydrocortisone, dapsone and clofazimine were started, and clinical improvement and decreased inflammatory markers followed. The patient was discharged with a 20-week course of prednisone and multidrug treatment for drug-susceptible pulmonary tuberculosis and leprosy. Concomitant Hansen's disease should be considered when treating patients for tuberculosis especially in areas where both are prevalent as different long-term multidrug regimens are required."

Journal • Dermatology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Pseudoprogression, ICI Pneumonitis, and Dapsone-Induced Methemoglobinemia in Pleural Mesothelioma: A Case Report (ATS 2026) - No abstract available

Case report • Clinical • Hematological Disorders • Malignant Pleural Mesothelioma • Mesothelioma • Pleural Mesothelioma • Pneumonia • Solid Tumor

Bisphenol A Alternatives in Follicular Fluid: Novel Risk Factors for Ovarian Reserve Dysfunction. (PubMed, ACS Omega) - "Spearman's correlation analysis showed that most BPs exhibited positive correlations (r = 0.20-0.61, p < 0.05), except dapsone (DDS). Ordinal logistic regression analysis showed that BPA, bisphenol AF (BPAF), benzyl 4-hydroxybenzoate (PHBB), DDS, and bisphenol F (BPF) were associated with ovarian reserve markers outside the normal range. In summary, this study confirms the widespread presence of BPA alternatives in the ovarian environment, suggesting their potential role in ovarian dysfunction and emphasizing the need for further mechanistic research and longitudinal follow-up studies."

Journal • Polycystic Ovary Syndrome